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Background: Cystic fibrosis (CF) is the most common life-threatening inherited disease in the Caucasian
population. It is caused by genetic defects in the cystic fibrosis transmembrane conductance regulator gene (CFTR), a
cAMP regulated chloride-bicarbonate channel mainly located in the apical membrane of polarized epithelial cells.
CFTR is proposed to regulate other proteins, including the epithelial sodium channel (ENaC). Recently, we
successfully restored chloride current in CFTR deficient human airway epithelial cells using wtCFTR-mRNA
transfection compared to non-CF cells showing similar values. The present study aimed to optimize the
wtCFTR-mRNA transfection procedures in primary cultured human nasal epithelial (HNE) cells.
Methods: Dose and time dependence experiments were performed. In addition, we investigated the possible impact of
the wtCFTR-mRNA transfection on ENaC function in transepithelial measurements. We reduced the wtCFTR-mRNA dose
stepwise and determined the minimal concentration of 0.6 μg/cm2, which is needed for the most efficient restoration of
CFTR function. Furthermore, CFTR expression was evaluated 24, 48 and 72 h after transfection.
Results: Using the minimal concentration of 0.6 μg/cm2 wtCFTR-mRNA we confirmed a positive functional CFTR
restoration over a period of 72 h. Biochemical analyses confirmed these findings. Furthermore, we could not find any
significant effect on ENaC after the recovery of CFTR by wtCFTR-mRNA transfection.
Conclusions: Our data show that wtCFTR-mRNA transfection is an encouraging alternative “gene” therapy in human
primary culture.
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Cystic fibrosis (CF) is a life-limiting autosomal recessive
disorder in the Caucasian population, affecting around
70.000 individuals worldwide. The disease is caused by
genetic defects in the cystic fibrosis transmembrane con-
ductance regulator gene (CFTR) that encodes for a cyclic
adenosine monophosphate (cAMP) -regulated chloride
channel. CFTR is expressed in the plasma membrane of
secretory epithelia- such as airways, intestine, pancreas,
testis and exocrine glands- as well as in some non-
epithelial cells types [1]. At the cell membrane CFTR
exhibits its function as a chloride channel and it is pro-
posed to regulate other membrane proteins, including
the epithelial sodium channel (ENaC) [2]. CFTR and
ENaC play the most important role in maintaining* Correspondence: wmw@uni-muenster.de
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ling the movement of water through the epithelium, thus
regulating the hydration of the epithelial surface in many
organs, but predominantly in the airways. It has been
demonstrated that Na+ absorption is enhanced in CF air-
ways and contributes to the pathogenesis of the disease
[3]. However, the interactions between CFTR and ENaC
are still not fully understood and the mechanism (s) re-
main unknown [4]. The defect in CF cells due to the im-
paired chloride transport and ion transport disturbances
evokes abnormally viscous secretions in the airways caus-
ing obstructions that lead to bacterial infections [5], in-
flammation, tissue damage and destruction of the organ.
Obstructive lung failure is currently the primary cause of
morbidity and is responsible for 80 % of mortality [6].
The discovery of the CFTR gene in 1989 [7] created
new possibilities for a curative treatment targeting the
basic defect rather than treating the symptoms of the CFle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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has been increased substantially [9] over the last few de-
cades in the treatment of CF. Gene therapy has been
pointed out as the forefront to overcome this difficult
challenge [10]. The potential of mRNA for therapeutic
protein expression in vivo has been investigated as an al-
ternative to DNA-based gene therapy. The preclinical ex-
ploration in the 1990s of the synthetic mRNA was
initiated for diverse applications, including protein substi-
tution for cancer and infectious diseases [11, 12]. Never-
theless, cancer immunotherapy is the only field in which
clinical testing of mRNA is at an advanced stage [13].
Recently, we established a new strategy to deliver CFTR-
mRNA directly to epithelial cells [14]. We showed a proof-
of-concept for mRNA-based functional restoration of
impaired CFTR functions in the cell culture, either using
human bronchial CF cells (CFBE41o-) that stably express
the most common mutation F508del-CFTR or primary cul-
tured human epithelial (HNE) cells [14]. We showed that
after mRNA transfection the CFBE41o- cells functionally
act very similar after cAMP stimulation compared to
healthy bronchial epithelia cells (16HBE41o-). Furthermore,
the amount of functional CFTR molecules in the CF cells
after mRNA transfection is even larger than in non-CF con-
trol cells [14]. Using the CF cell line or HNE cells wtCFTR-
mRNA transfection procedures were performed using a
dose of 2.4 μg/cm2 and 24 h after transfection the analyses
were carried out.
In order to give more physiological relevance we only
used primary HNE cells in our study. In vitro cell culture
models of human nasal epithelium based on primary cul-
ture technologies are known to be extremely useful for
permeability and transport studies in healthy and disease
tissues [15]. Furthermore, cultured nasal cells are reliable
models since they are known to express important bio-
logical features such as tight junctions, mucin secretion,
cilia, transporters comparable to those found in vivo sys-
tems [16]. Thus, the use of primary human nasal cell cul-
ture systems could accurately represent an alternative to
in vivo situations. In addition, nasal epithelial cells could
be used as a substitute for bronchial epithelial cells as they
show identical morphologies with similar expression of re-
ceptors and responses to cytokine stimulation [17].
The major purpose of the present study was to optimize
the dose of wtCFTR-mRNA as well as the determination of
the time for a suitable CFTR expression in primary HNE
cells. We determined the optimal mRNA concentration re-
ducing the transfection dose needed for the successful re-
covery of the CFTR function. Furthermore, we performed
time dependent studies with the minimal wtCFTR-mRNA
concentration in order to evaluate the duration of the
CFTR protein expression after mRNA transfection. In
addition, after the efficient restoration of CFTR function,
we investigated the possible impact of the CFTR-mRNAtransfection on ENaC. Since primary cultured nasal epithe-
lial cells show only a low chloride secretion but a positive
amiloride-sensitive ENaC current, it is an excellent cell
model for the investigation of CFTR and ENaC interactions
[4]. We concluded that mRNA delivery, termed “transcript
therapy” [18] is an encouraging alternative in human pri-
mary culture offering a promising opportunity for the study
of CF and the potentially clinical therapies in patients suf-
fering from this incurable disease.
Methods
mRNA synthesis
For in vitro transcription (IVT) we used the pSTI‐
A120/hCFTR cDNA (construct provided by C. Rudolph,
Maximilian University of Munich, Munich, Germany).
The mRNA synthesis was performed as described previ-
ously [14]. Briefly, the linearized plasmids were extracted
with phenol/chloroform and precipitated with ethanol.
The IVT reaction was carried out using the mMessage
mMachine Kit (Ambion, Foster City, USA). The reaction
was purified using the RNeasy plus Mini Kit (Quiagen,
Hilden, Germany) and ethanol/ammonium acetate pre-
cipitation was done to achieve good quality. The con-
centration of mRNA was determined by absorbance
measurement at 260 nm using a microvolume spectro-
photometer (Nanodrop, Thermo Scientific, Wilmington,
DE, USA). The integrity and size distribution of mRNA
was determined by agarose gel electrophoresis and eth-
idium bromide staining. The generated mRNA was stored
at −80 °C in nuclease-free water.
Cell culture
Primary cell culture of HNE cells was performed as de-
scribed previously [19]. Briefly, cells were isolated by en-
zymatic digestion for 24–72 h and afterwards seeded on
collagen coated (0.15 mg/ml collagen type I; Biochrom
AG, Berlin, Germany) Transwell permeable filters (diam-
eter 6.5 mm, Costar 3470; Corning Inc., Lowell, MA,
USA) for transepithelial measurements, on coated cell
culture dishes (diameter 35 mm) for biochemistry ana-
lyses or on coated glass coverslips (diameter 12 mm) for
optical fluorescence assays. The cells were cultured with
serum-free F-12 Nutrient Mixture (Ham) (Invitrogen/
Gibco, Kahlsruhe, Germany) supplemented with insulin
(2 g/ml) (Invitrogen, Gibco), epidermal growth factor
(12 ng/ml) (Sigma, Deisenhofen, Germany), endothelial
cell growth supplement (7.5 g/ml) (Becton Dickinson
GmbH, Heidelberg, Germany), triiodo-thyronine (3 nM)
(Sigma), hydrocortisone (100 nM) (Sigma), gentamycin
(10 g/ml) (Biochrom AG), penicillin/streptomycin (100 U/
ml) (Invitrogen/Gibco), L-glutamine (2 mM) (Invitrogen/
Gibco) and transferrin (4 g/ml) (Invitrogen/Gibco). Fibro-
blast contamination is reduced by the use of serum-free
media and cluster formation is avoided by filtering through
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HNE cells was confirmed using specific antibodies against
vimentin and keratin. Cells were incubated in 95 % air and
5 % CO2 at 37 °C. Cells were seeded on the membrane
and a confluent monolayer was obtained after 7 to 9 days.
Transfection efficiency and fluorescence optical analyses
The in vitro transfection efficiency of LipofectamineTM
2000 (Invitrogen) was evaluated in HNE cells using the
pEGFP-C1 plasmid (Clontech/Takara Bio Europe, Saint-
Germain-en-Laye, France). Co-transfection of pEGFP-C1
and GFP- siRNA and H2O transfections were used as con-
trols. Cells were seeded on coverslips 2 days before trans-
fection and were cultivated in HNE culture medium. The
day of transfection confluence of the cells was greater than
80 %. Three hours before transfection, cells were culti-
vated in HNE culture medium without antibiotics. Cells
were transfected with 1 μg of pEGFP-C1 or co-transfected
with 2.5 pmol/cm2 GFP-siRNA (negative control) or a re-
spective amount of nuclease free water. After 48 h of incu-
bation, cells were fixed with 0.05 % glutaraldehyde and
autofluorescence was quenched with 0.1 % sodium boro-
hydride. Analysis of the fluorescence intensities was deter-
mined using a fluorescence microscope (LSM 510 META;
Carl Zeiss, Oberkochen, Germany). The images were re-
corded using the AxioCamMRm and the LSM 510 4.2
SP1 software (Carl Zeiss). The exposure time was adjusted
manually for comparison of total fluorescence intensities.
For compensation images, confluent regions of the cell
layer were used for the analysis.
wtCFTR-mRNA transfection procedure
For transfection experiments HNE cells were seeded on
collagen coated Transwell permeable filters or on coated
cell culture dishes and cultivated for 7 to 9 days. The cell
culture medium was replaced every 2 days. Twenty-four
hours before transfection, the medium was removed,
and fresh HNE culture medium without antibiotics was
added. In all experiments, LipofectamineTM 2000 was
used as transfection reagent. The experiments were per-
formed in accordance to the manufacturer’s instructions
using Opti-MEM as transfection medium. Transfection
complexes were replaced after 4–6 h with normal HNE
culture medium.
Dose dependence studies
Cells were transfected with different concentrations of
wtCFTR-mRNA (2.4 μg/cm2, 1.2 μg/cm2, 0.6 μg/cm2,
0.3 μg/cm2) and experiments were performed 24 h after
transfection.
Time dependence studies
HNE cells were transfected with the optimal concentration
of 0.6 μg/cm2 and analyses were carried out 24, 48 and
72 h after transfection.Transepithelial measurements
Modified Ussing chambers designed by Prof. Willy Van
Driessche (KU Leuven, Belgium) were used to perform
the transepithelial measurements. Ag/Ag electrodes were
connected to Ringer solution (130 mM NaCl, 5 mM
KCl, 1 mM CaCl2, 2 mM MgCl2, 5 mM glucose and
10 mM HEPES, pH 7.3, 37 °C) and the transepithelial
potential (Vt) was clamped to zero. The two compart-
ments of the Ussing chamber, apical and basolateral, were
continuously perfused with cell culture Ringer solution.
The short-circuit current (Isc), which reflects the trans-
ported net charges over the epithelium was constantly
monitored (ImpsDsp 1.4; KU Leuven). The parameter was
normalized to 1 cm2. After stabilization of the parameters,
a cAMP (8-[4-chlorophenylthio (CTP)]-cAMP) (100 mM;
Biolog, Bremen, Germany)/ IBMX (1 mM; ApplieChem
GmbH, Darmstadt, Germany) cocktail was applied on the
basolateral side to activate CFTR. Subsequently, CFTR
was inhibited using the specific blocker CFTRinh172
(20 μM; Tocris Bioscience, Bristol, UK). In addition, the
Na+ absorption through ENaC was assessed as short-
circuit current in the presence and absence of amiloride
(100 μM). Therefore, the effect of the wtCFTR-mRNA
transfection on the amiloride current via ENaC was inves-
tigated. If not otherwise stated, all chemicals were ob-
tained from Roth (Karlsruhe, Germany).
Protein biochemistry
For Western Blot experiments HNE cells were detached
from culture dishes using 400 μl of lysis buffer (1 mM
Tris, 15 mM NaCl, 0.2 mM EDTA, 2 % Triton X-100)
and 1 % protease inhibitor cocktail (Sigma). The extracts
were homogenized with a sonifier ultrasonic cell dis-
rupter (Branson, Danbury, CT, USA) and placed on ice
for 10 min. The lysate was centrifuged at 4000 g for
30 min at 4 °C to pellet the cell debris and the super-
natant was used. The concentration of the proteins was
determined using the BCA test (Pierce, Rockford, IL,
USA). 40 μg total protein were separated via SDS-PAGE
(7.5 % acrylamide) and subsequently transferred to a
polyvinylidene fluoride PVDF membrane using a semi-
dry blotting system. Non-specific bindings sites were
blocked for 2 h at RT with 5 % non-fat dry milk in Tris-
buffered saline/Tween (TBS-T: 10nM Tris HCl, pH 7.4;
140 nM NaCl; 0.05 % Tween 20). CFTR protein was de-
tected using an anti- CFTR antibody (ABR-01129; Dia-
nova, Hamburg, Germany) in a 1: 500 concentration
diluted in 5 % non-fat dry milk/TBS-T overnight at 4 °C
continuously shaking. Vimentin and keratin proteins
were detected using anti-vimentin and anti-keratin anti-
body, respectively (Dianova, Hamburg, Germany) in a 1:
500 concentration diluted in 5 % non-fat dry milk/TBS-T
overnight at 4 °C continuously shaking. After 24 h, the
membrane was washed in TBS-T three times for 10 min
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mouse Ig G conjugated with horseradish peroxidase (HRP)
(Dianova) diluted 1: 10,000 in 5 % non-fat dry milk/TBS-T
for one hour at room temperature continuously shaking.
Then, the membrane was washed again three times in
TBS-T for 10 min and once in TBS. The detection was car-
ried out with enhanced chemiluminiscence (ECL). To
assure comparable protein amount and expression, anti-
alpha-tubulin (Tubulin, alpha, DLN-09993; Dianova) was
used for normalization. Image J, version 1.41 (Wayne Ras-
band, National Institutes of Health, Bethesda, MD, USA)
was used for densitometry evaluation of the CFTR band
intensity.
Analysis of fluorescence intensities
Analysis of total fluorescence intensities was performed
using ImageJ, version 1.41. The plug-in for RGB (Red,
Green, Blue) measurement analyses the intensity of each
channel of an image and displays the average channel in-
tensity [(R + G + B)/3]. The generated value was employed
for analysis and was compared with that of other images.
The average of non-transfected cells was set to 100 % and
the transfected average was normalized to that value to be
expressed as a multiple of the non-transfected value.
Statistical analysis
Data are presented as the arithmetic means (± SEM). Sets
of data were compared with Student’s t-test. Differences
were considered statistically significant when p < 0.05 (*)
or p < 0.01 (**). In all experiments, n gives the number of
replications. All statistical tests were performed using Ori-
gin, version 7.0 (Originallab Corporation, Northampton,
USA).
Results
Characterization of primary HNE cells
The determination of the purity of the HNE culture is a
key factor in order to validate further experiments.
Vimentin is the main intermediate filament inFig. 1 Representative Western blot. Proteins (40 μg) from two human bronchi
epithelial (HNE) cells and human umbilical vein endothelial cells (HUVEC) were
identify the characteristic protein bands of vimentin (a) and keratin (b) we used
antibody (Dianova), respectively. As secondary antibody we used a goat anti-mo
of vimentin in the range of 57–60 kDa solely in the HUVEC sample and a specifmesenchymal cells and was used to detect non-epithelial
cells. The primary human umbilical vein endothelial
cells (HUVEC) served as positive control for vimentin
expression [20]. In Western blot experiments (see Fig. 1)
a specific band of vimentin was detected in the range of
57–60 kDa solely in the HUVEC sample, while in the
other samples, the human bronchial epithelial cell lines
(16HBE14o- and CFBE41o-) and primary HNE cells any
band was found. Additionally, a specific band for keratin
in the range of 45 kDa in all separated samples
(HUVEC, 16HBE14o-, CFBE41o- and primary HNE
cells) was detected. As expected, no vimentin expression
in the analyzed cells, except for HUVEC, was observed.
Hence, the characterization of the HNE cells as pure
epithelial cells was verified.
Transfection efficiency
The transfection efficiency was determined for the primary
cultured HNE cells. It is expressed as the proportion of cells
that express the transgene among all cells in the culture
dish. In addition, multiple experimental factors (transfec-
tion method, health and viability of the cells, degree of con-
fluence, etc.) can influence the transfection procedure [21].
High transfection efficiencies and low toxicity are the pri-
mary requirements of an ideal gene delivery vector [22]. In
this approach, the green fluorescence protein (GFP) was
used as a reporter. In Fig. 2, representative fluorescent im-
ages of pEGFP transfected cells are shown. The intensity of
the fluorescent signal is used as an indicator of transfection
efficiency. The statistical evaluation of the fluorescence in-
tensities is shown in Fig. 2 and demonstrates that cells
transfected with pEGFP exhibited considerable elevated
fluorescence as compared to controls after 24 h. The total
fluorescence intensity in GFP transfected cells was almost
226 % higher as compared to the controls. The different
negative controls reflect fluorescence intensities similar to
control cells in all experiments. Analyzing this data, high
transfection efficiencies for the primary cultured cells using
Lipofectamine as transfection reagent were observed.al epithelial cell lines (16HBE14o- and CFB41o-), primary human nasal
isolated by using 2 % Triton X-100 and separated on a 10 % SDS-PAGE. To
a mouse monoclonal anti-vimentin and a mouse monoclonal anti-keratin
use IgG-HRP conjugated antibody (Dianova). We detected a specific band
ic band of keratin in the range of 45 kDa in all separated samples
Fig. 2 Transfection efficiency of HNE cells. Cells were analyzed 24 h after transfection. a Samples transfected with GFP (a) exhibited a markedly increased
fluorescence as compared to controls after 24 h (b: water transfected, c: nonbinding siRNA, d: non-transfected). b Statistical evaluation of
fluorescence intensities of the primary HNE cells. An increase of approximately 226 % is shown in GFP transfected cells compared to the controls.
Measurements of the different negative controls revealed fluorescence intensities comparable to control cells in all experiments (*p≤ 0.05; **p≤ 0.01)
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Electrophysiological measurements
In initial studies, the transfection of primary cultured
HNE cells was performed using an mRNA concentration
of 2.4 μg/cm2 and 24 h after transfection transepithelial
measurements were carried out. The statistical analysis
revealed a successful increase of almost two-fold of the
CFTR current in transfected cells compared to controls
(non-transfected cells) [14]. Because of these positive re-
sults, dosage was stepwise reduced (2.4 μg/cm2, 1.2 μg/cm2, 0.6 μg/cm2, 0.3 μg/cm2) in order to find the minimal
concentration that is sufficient for the restoration of the
functional cAMP dependent CFTR current. Therefore,
confluent monolayer of primary cultured HNE cells were
used to measure the transepithelial short-circuit current
(Isc) in the Ussing chamber. Generally, in HNE cells, the
CFTR activation is not markedly increased due to the low
expression of the CFTR protein in the nasal tissue
[23, 24]. After the application of the cAMP-cocktail, Isc
was increased (2.8 ± 0.5 μA/ cm2; n = 39) in the control
Fig. 3 Time course of a typical transepithelial measurement. Shown is
the short circuit current (Isc) in HNE cells (non-transfected = controls)
(a) and wtCFTR-mRNA transfected HNE cells (b) respectively. After
the application of the cAMP-cocktail Isc smoothly increased in the control
cells as shown in (a). In a second step, the chloride current was inhibited
with the specific inhibitor CFTRinh172. When HNE cells were transfected
with wtCFTR-mRNA, Isc increased, by the application of cAMP, which
could be inhibited by the inhibitor CFTRinh172. The cAMP activation of
CFTR is boosted by the transfection demonstrating functional expression
of CFTR
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wtCFTR-mRNA, a markedly increase (5.2 ± 0.6 μA/ cm2;
n = 36) of the short-circuit current (Fig. 3b) was ob-
served, demonstrating successful expression of CFTR
after wtCFTR-mRNA transfection. Moreover, in a second
step, this functional expression of CFTR was also inhibited
by the specific CFTR blocker CFTRinh172, resulting in a
decrease in the CFTR current. A dose-dependent increase
of the CFTR circuit current was observed after decreasing
the concentration of wtCFTR-mRNA from 2.4 to 0.6 μg/
cm2 (Fig. 4). Therefore, when reducing the mRNA amount
to 0.6 μg/cm2, it was observed that this concentration is the
minimal and also the most suitable dose to achieve an in-
crease in the CFTR current (9.3 ± 2.0 μA/ cm2; n = 19). Re-
ducing the concentration to 0.3 μg/cm2 wtCFTR-mRNA,
the Isc was significantly decreased after the application of
the cAMP/IBMX cocktail (2.5 ± 2.4 μA/ cm2; n = 6). In
control cells, the application of the inhibitor had no effect
on the current, while in wtCFTR-mRNA transfected cells
with a dose of 0.6 μg/cm2 (n = 19) a 72.93 % inhibition of
the cAMP activated CFTR current was observed. The in-
creased inhibition of CFTR current in HNE cells trans-
fected with 0.6 μg/cm2 wtCFTR-mRNA may demonstrate
that more CFTR molecules are expressed after mRNAtransfection than in control cells (non-transfected). As a
concentration of 0.6 μg/cm2 wtCFTR-mRNA had the
strongest effects on CFTR current, all further experiments
were performed with this concentration.
Western blot analyses
To test whether the transfection of wtCFTR-mRNA in-
creases CFTR protein level, we analysed the expression of
CFTR concerning to the mRNA dose in HNE cells and
subsequently we carried out semi-quantitative Western
blot assays with a specific monoclonal anti-CFTR antibody.
This antibody detects a CFTR band in the range of 170
kDa (Fig. 5). Tubulin was used as a control in the WB ex-
periments for the further normalization analyses. The band
of tubulin is detected in the range of 55 kDa. The transfec-
tions with the different wtCFTR-mRNA doses (2.4 μg/cm2,
1.2 μg/cm2 0.6 μg/cm2) were performed and 24 h after
Western blot assays were carried out. We found a nearly
doubled (1.8-fold) CFTR protein expression when using
the minimal dose of 0.6 μg/cm2. These results confirm our
findings of the electrophysiological analyses and demon-
strate that 0.6 μg/cm2 wtCFTR-mRNA is the optimal dose
for the overexpression of CFTR in primary HNE cells.
Time response studies
Electrophysiological measurements
We evaluated if the positive wtCFTR-mRNA transfec-
tion effect could sustain the CFTR function over a longer
period of time. Therefore, the persistence of the CFTR ex-
pression 24, 48 and 72 h after transfection with the optimal
dose of 0.6 μg/cm2 mRNA μg/cm2 was analysed. To inves-
tigate this, we carried out transepithelial measurements in
modified Ussing chambers. In Fig. 6 the Isc the time
dependent decrease is shown. The highest CFTR
restoration was achieved 24 h (9.3 ± 2.0 μA/ cm2; n = 19)
after CFTR-mRNA transfection. After that point a gradual
decrease was observed. Nevertheless, over a period of 72 h
the CFTR mediated current was still confirmed (5.2 ±
0.6 μA/ cm2; n = 6) compared to controls (2.8 ± 0.5 μA/
cm2; n = 35). In addition, the inhibition by the specific in-
hibitor CFTRinh172 is expanded in the wtCFTR-mRNA
transfected cells but was not observed in the control cells
24 h after transfection we measured a 72.93 % inhibition of
the cAMP activated CFTR current, which was still ob-
served 72 h after transfection (27.08 %). These results show
that even after 72 h after wtCFTR-mRNA transfection an
increase in CFTR current was observed.
Western blot analyses
In addition, we performed Western Blot assays using a spe-
cific antibody that binds to CFTR. HNE cells were trans-
fected with the optimal dose of 0.6 μg/cm2 CFTR-mRNA
and 24 and 48 h experiments were performed. To identify
CFTR, we used a monoclonal anti-CFTR antibody that
Fig. 4 Statistical evaluation of the wtCFTR-mRNA dose dependency. a Shown are the short-circuit values (Isc) of CFTR activation by cAMP addition
and the inhibition by CFTRinh172 application in HNE cells. The stepwise decrease of the transfection dose (2.4 μg/cm2, 1.2 μg/cm2, 0.6 μg/cm2
and 0.3 μg/cm2) produced CFTR activation after the cAMP application. The most efficient CFTR activation was reached using the mRNA dose of
0.6 μg/cm2 (9.3 ± 2.0 μA/ cm2; n = 19) compared to the controls cells (2.8 ± 0.5 μA/ cm2; n = 39). The subsequent reduction to a concentration of
0.3 μg/cm2 did not show any proper activation of CFTR. b The inhibition by the CFTRinh172 is also increased in the wtCFTR-mRNA transfected
cells. Although, we could not observe a reduction by the inhibitor in the control cells, we found a 72.93 % inhibition of the cAMP activated CFTR
current in the wtCFTR-mRNA transfected cells with a dose of 0.6 μg/cm2 (n= 19). The higher rate of inhibition in transfected HNE cells with the dose of
0.6 μg/cm2 may demonstrate that more CFTR molecules are expressed after mRNA transfection than in control cells (non-transfected) (*p< 0.05; **p< 0.01)
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we detected tubulin in the range of 55 kDa for
normalization analyses. Figure 7 shows the statistical evalu-
ation of the relative CFTR protein amount. Twenty-four
hours after wtCFTR-mRNA transfection 1.5-fold more
CFTR protein is expressed. These results confirm our find-
ings of the electrophysiological analysis.
Influence of wtCFTR-mRNA on ENaC
Cells of HNE were stepwise transfected with different con-
centrations of wtCFTR-mRNA (2.4 μg/cm2, 1.2 μg/cm2,
0.6 μg/cm2) and 24 h before the experiments in modified
Ussing chambers were carried out. Furthermore, time de-
pendence studies 48 and 72 h using 0.6 μg/cm2 wtCFTR-mRNA were performed. Na+ absorption by ENaC was
assessed as short-circuit current in the presence and ab-
sence of amiloride (100 μM). To determine the overall Na+
absorption of the cells, Na+ was removed from the apical
Ringer in a second step. Transfection of HNE monolayers
with wtCFTR-mRNA resulted in a decreasing trend due to
amiloride response, indicating that the expression of ENaC
is reduced by wtCFTR-mRNA transfection: 2.4 μg/cm2
(32.85 % ± 3.8; n = 34), 1.2 μg/cm2 (27.92 % ± 5.1; n = 18)
and 0.6 μg/cm2 (25.03 % ± 5.9; n = 19). Nevertheless, the
statistical evaluation (Fig. 8) of the performed measure-
ments revealed no significant differences between the dif-
ferent mRNA doses with regard to the amiloride sensitive
current. Therefore, only a decreasing tendency in the
Fig. 5 Western blot analyses. Total membrane proteins (40 μg) from HNE cells were isolated using 2 % Triton X-100 and separated in a 7.5 % SDS-PAGE.
To identify CFTR, we used a monoclonal anti-CFTR antibody that detects a CFTR band in the range of 170 kDa. In addition, we detected tubulin in the
range of 55 kDa for normalization analyses. a HNE cells were transfected with different CFTR-mRNA doses (2.4 μg/cm2, 1.2 μg/cm2, 0.6 μg/cm2).
b Statistical evaluation of the relative CFTR protein amount in transfected cells. Transfection with a CFTR-mRNA dose of 0.6 μg/cm2 expressed 1.8-fold
more CFTR protein. These results verify the efficiency of the 0.6 μg/cm2 dose as an optimal wtCFTR-mRNA concentration for CFTR expression
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side, time dependence studies showed an increasing trend
in the amiloride sensitive current (Fig. 8). The expression
of ENaC is increased by the wtCFTR-mRNA transfection:
24 h (25.03 % ± 5.9; n = 19), 48 h (29.51 % ± 8.1) and 72 h
(29.44 % ± 12). However, no statistical differences were
found revealing no measurable effect of wtCFTR-mRNA
transfection on ENaC.
Discussion
The discovery of the disease-causing CFTR gene in 1989
[7] created new hopes for a curative treatment targeting
the basic defect rather than treating CF disease manifes-
tations [8]. Since this CFTR identification, there has
been significant efforts to develop gene therapy strat-
egies for the correction of the mutation on cellular level.
The delivery of a therapeutic nucleic acid (DNA or
RNA) is a promising concept for an inherited single-
gene defect such as CF, with the prospect of correcting
many aspects of the complex pathology [25]. In addition,
one single therapy might be suitable to treat subjects
with a wide variety of mutations, meaning that a single
treatment strategy would be relevant to all patients.However, initially approaches, which involved direct ad-
ministration to the airway of recombinant CFTR based
on conventional viral DNA-delivery have not been suc-
cessful for a number of reasons [26]. Subsequently, the
development of mRNA-based therapeutic approaches
presents several important differences in comparison
with other nucleic acid-based therapies [27] like the dir-
ect translation in the cytoplasm, the missing integration
into the genome and therefore the avoidance of the po-
tential risk of insertional mutagenesis [28]. Therefore, as
already described by our working group, we developed a
new strategy using mRNA instead of DNA to correct
CFTR function in the apical plasma membrane of hu-
man CF airway epithelia after wtCFTR-mRNA transfec-
tion in vitro [14]. Although other organs are affected in
CF as well, the lung is the major site of pathology and
thus, has been the target in the majority of gene ther-
apy trials. Consequently, most investigators have fo-
cused towards minimizing CF lung disease [29]. In fact,
the best target for the CF gene therapy in the airways
are the ciliated epithelial cells [28]. Although it is
known that CFTR constitutes a low-abundance mRNA
in airway epithelia [30] a minor level of CFTR gene
Fig. 6 Statistical evaluation of the wtCFTR-mRNA time dependency. Shown are the short-circuit values of CFTR activation by cAMP addition and
the inhibition by CFTRinh172 application in HNE cells. a The cAMP activated chloride secretion is decreased according to time periods. Twenty-four hours
after mRNA transfection with the optimal dose of 0.6 μg/cm2 the highest CFTR expression (9.3 ± 2.0 μA/ cm2; n= 19) was achieved. In comparison, longer
time periods produced a decrease in the CFTR current. Nevertheless, we confirmed a positive CFTR activation over a period of 72 h (5.2 ± 0.6 μA/ cm2;
n = 6). b The inhibition by the CFTRinh172 is expanded in the wtCFTR-mRNA transfected cells. Since we could not observe a reduction by
the inhibitor in the control cells, we found a 72.93 % inhibition of the cAMP activated CFTR current in wtCFTR-mRNA transfected cells after
24 h (n = 19). Therefore, the CFTR inhibition was found 48 h (37.18 %) and even 72 h after transfection (27.08 %) (*p < 0.05; **p < 0.01)
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Cl− transport in vitro and in vivo [31]. Furthermore, only
10 % of normal cells are sufficient to normalize the
main dysregulated parameters such as Cl− or Na+
conductance and IL8 secretion [32].
Dose and time dependence studies
We used primary cultured human epithelial cells to
perform our mRNA transfection experiments in a lipid-
based transfection reagent to produce overexpression of
CFTR protein. We have found that CFTR-mRNA can be
effectively delivered in these primary cultured cells and
that the expressed proteins are functional. The aim of thisstudy was to find the optimal mRNA dose that is needed
for an efficient chloride secretion mediated by the CFTR
channel and to study the persistence of the wtCFTR-
mRNA transfection over a period of time. Therefore, we
carried out Ussing chambers experiments and measured
the transepithelial current (Isc) in transfected HNE cells
and in non-transfected cells. We performed dose
dependent studies, in which a stepwise dosage reduction
was carried out, from 2.4 to 0.3 μg/cm2. In these measure-
ments, we found that the most efficient CFTR activation
was reached using a mRNA dose of 0.6 μg/cm2 compared
to non-transfected cells. Furthermore, CFTR mediated
current in time experiments studies confirmed that
Fig. 7 Western blots analyses. Total membrane proteins (40 μg) from HNE cells were isolated using 2 % Triton X-100 and separated in a 7.5 % SDS-PAGE.
To identify CFTR, we used a monoclonal anti-CFTR antibody that detects a CFTR band in the range of 170 kDa. In addition, we detected tubulin in the
range of 55 kDa. a HNE cells were transfected with wtCFTR-mRNA (0.6 μg/cm2) at different time periods (24 h, 48 h). b Statistical evaluation of the relative
CFTR protein amount in transfected cells. Twenty-four hours after wtCFTR-mRNA transfection the amount of CFTR protein was increased
(1.5-fold) compared to controls
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ent over a period of 72 h.
Accordingly, we verified these findings using protein
biochemistry analyses. First, we analysed the amount of
CFTR using Western blot procedures. Thus, we showed
that the HNE cells transfected with 0.6 μg/cm2 expressed
nearly twice as much CFTR protein compared to control
cells. These biochemical results correlate perfectly with
the increase in the cAMP-induced current observed in the
electrophysiological analyses. In time dependence studies,
24 after 0.6 μg/cm2 wtCFTR- mRNA transfection 1.5- fold
more CFTR protein compared to non-transfected cells
was shown. Here, the obtained results indicated that the
functional CFTR protein can be maintained in the plasma
membrane over a few days in HNE cells. Nonetheless,
after 48 h less protein are detectable due to the potential
degradation of the CFTR. CFTR expression using unmodi-
fied mRNA decreased within 3 days, requiring repeated
application in high frequencies [33, 34]. Moreover, possible
difficulties in long-term effect may also include mRNA sta-
bility and therefore the duration of the mRNA effect in the
target cells, which could make frequent dosing necessary.Does the boosted CFTR expression affect ENaC?
In CF disease, salt and fluid absorption is prompted by
the loss of CFTR and the inappropriate regulation of
ENaC [3]. The consequence is an increase in water and
sodium reabsorption from the airways, compromising
the formation of a sufficient periciliary liquid layer and
mucus clearance [35]. In CF airways, ENaC is stimulated
by the increase in cAMP concentrations when functional
CFTR is lacking, suggesting that CFTR acts in decreas-
ing ENaC activity [35–37]. To better understand CFTR/
ENaC interactions as well as to determine the role of
ENaC in wtCFTR-mRNA transfection experiments in
primary cultured human epithelial cells, electrophysio-
logical measurements in Ussing chambers were carried
out to study ENaC activity in the presence of boosted
CFTR expression. As expected, the control cells had the
highest amiloride-sensitive current. It is well known that
primary HNE cells have an amiloride-sensitive current
[38, 39]. In comparison, in cells transfected with differ-
ent doses of wtCFTR-mRNA the transepithelial ENaC
current decreased stepwise, possibly showing a trend in
the down-regulation of ENaC by CFTR (Fig. 8a).
Fig. 8 Statistical evaluation of the amiloride-sensitive current in
dependence of the wtCFTR-mRNA. a Shown is the decreasing
trend in ENaC expression in primary HNE cells 24 h after wtCFTR-mRNA
transfection using different concentrations 2.4 μg/cm2 (32.85 % ±
3.8; n= 34), 1.2 μg/cm2 (27.92 %± 5.1; n= 18), 0.6 μg/cm2 (25.03 %± 5.9;
n= 19). There is no statistical significance. b Shown is the increasing
trend in ENaC expression in primary HNE cells after 0.6 μg/cm2 wtCFTR-
mRNA transfection using different time periods: 24 h (25.03 % ±
5.9; n = 19), 48 h (29.51 % ± 8.1) and 72 h (29.44 % ± 12). No statistical
difference was found
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and therefore no effects of the transfection on ENaC
function or expression were confirmed. On the other
side, in time dependence studies an increasing trend in
the amiloride-sensitive current was found (Fig. 8b), al-
though no statistical difference was found, too. In a cer-
tain way, these results indicate a down-regulation of
ENaC by CFTR. Firstly, the inhibition of ENaC was
shown by a decreasing tendency in the amiloride-
sensitive current after overexpression of CFTR with dif-
ferent wtCFTR-mRNA doses. Secondly, the restoration
of ENaC was measured by an increasing trend of ENaC
current after wtCFTR-mRNA transfection in time de-
pendence experiments. Further studies, not only func-
tional electrophysiological measurements but also
biochemical and immunological studies are necessary to
confirm these findings. In summary, more than 20 years
after the initial discovery that ENaC’s sensitivity tocAMP is CFTR dependent, the mechanism of the
CFTR/ENaC interaction, and in particular the ENaC
regulation by CFTR, still remains unclear. Undoubtedly,
ENaC represents an attractive alternative target to im-
prove airway surface hydration and mucus clearance in
patients with CF independent of their CFTR genotype.
Different delivery methods
In CF pulmonary disease the opportunity to selectively
target a drug to the lungs remains a fascinating option
[40]. In fact, local drug delivery may allow maximum
pharmacological targeting, and thus therapeutic efficacy.
As a consequence, researchers continue applied efforts
to develop new inhalation devices and advanced drug
delivery [41]. CFTR-mRNA aerosol administration to
airways of CF patients could be delivered as it was previ-
ously showed [42]. Furthermore, another study success-
fully demonstrates the gene delivery with magnetized
aerosol comprising iron oxide nanoparticles in lungs of
mice [43]. Therefore, administration of drugs via the in-
halation route is of great interest in CF treatment [44].
The main advantages of aerosol technologies are the
limited systemic toxicity, direct drug action on target
site and the suitability for home therapy [45]. An im-
portant issue in gene delivery is the biocompability and
biosafety of the nanocarrier used in the transfection pro-
cedure [46]. Lipid based formulations like cationic lipids
o cationic polymers have become a successful method to
transfect cells and to reach adequate transfection effi-
ciency in vitro [15, 47]. Here, this study demonstrates
promising results using this lipid-based delivery by Lipo-
fectamineTM 2000 transfection reagent in primary cul-
tured cells. On the other side, since Lipofectamine
presents a high cytotoxicity for the cell viability despite
its robust and high transfection efficiency [48], it is not an
appropriate carrier to assess potentially clinical in vivo ther-
apies in treatment of CF. Therefore, we are looking for an
alternative and stable formulation like biopolymers, e.g. chi-
tosan, that could be effective to target intratracheal routes.
Efficient transfection in a CF cell line may show the future
use of this nanocarrier in the gene therapy approaches.
Nevertheless, the search for an optimal transfection agent
is still open in the hope of finding a solution to address the
barriers associated by the lung.
Future aspects: clinical application/dosage form
One of the major milestones for a potential clinical applica-
tion of the mRNA based gene therapy is to circumvent un-
wanted immune responses, instability and delivery barriers.
Chemical modifications of the mRNA, like the inclusion of
pseudouridine in the mRNA prevented activation pattern
recognition receptors [49] and 2’-5’-oligoadenylate synthe-
tase [50]. Furthermore, these modifications can stabilize the
mRNA against cleavage and ultimately improve expression
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to avoid side effects and therefore the clinical application is
in sight [51]. In addition, efficient pulmonary drug delivery
has been mostly achieved through specific devices and par-
ticle engineering technologies [52]. The face of the future in
CF lung therapy is the development of easy to use dry pow-
der for inhalation [53]. In this context, biocompatible nano-
particles, such as chitosan nanoparticles, are very suitable
candidates because they permit an efficient protection of
the gene material and its delivery to airway epithelial cells.
In addition, despite chitosan biodegradability, future lung
deposition studies should achieve the issue of chitosan-
wtCFTR-mRNA complexes fate after they have landed. Fur-
thermore, other challenges concerning targeting the lung
should be considered because it is an immunologically sen-
sitive organ and the airway cells turn over [54]. For instance,
higher doses are generally required for the effective admin-
istration to the lung [28] and sustainable expression of the
therapeutic gene is difficult to achieve. Therefore, the poten-
tial dosage of chitosan-wtCFTR-mRNA complexes could
demand a repeated administration. Multi dose clinical trials
could achieve improvement in lung function, long-term ex-
pression and subsequently, future clinical benefits for CF
patients.
Conclusions
We have clearly demonstrated that wtCFTR-mRNA can be
effectively delivered in primary cultured human nasal epi-
thelial cells, and that the expressed proteins are functional.
Moreover, we have shown that CFTR-mRNA can be re-
duced to minimal dose and is persistent for a time period
longer than 24 h after transfection. Furthermore, we could
not find any effect on ENaC activity after the reconstitution
of CFTR by transfection. Our study establishes the efficient
mRNA transfection using primary cultured cells, thus cre-
ating the more physiological relevant conditions for further
approaches in the potentially development of therapeutic
strategies for CF disease treatment.
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